Osteoglycin deficiency does not affect atherosclerosis in mice

Atherosclerosis

Volumn 237, Issue 2, 2014, Pages 418-425

  Moncayo Arlandi, Javier ^a   López García, Alejandro ^b,c   Fernández, M Carmen ^b,c   Durán, Ana Carmen ^b,c   Fernández, Borja ^b,c  

^a GIRONA BIOMEDICAL RESEARCH INSTITUTE IDIBGI   (Spain)

^b UNIVERSITY OF MÁLAGA   (Spain)

^c Biomedical Research Institute of Malaga IBIMA   (Spain)

Author keywords

Apoe; Knockout mouse; Osteoglycin; Small Leucine Repeat Domain Protein

Indexed keywords

APOLIPOPROTEIN E; CALCIUM; DECORIN; MESSENGER RNA; MIMECAN; OSTEOGLYCIN; PROTEOGLYCAN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ARCH; AORTA ATHEROSCLEROSIS; AORTA SINUS; ARTICLE; ASCENDING AORTA; ATHEROSCLEROSIS; CALCIFICATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DISEASE COURSE; EXTRACELLULAR MATRIX; FEMALE; FOAM CELL; GENE INACTIVATION; KNOCKOUT MOUSE; MALE; MORPHOMETRICS; MOUSE; NONHUMAN; OSTEOGLYCIN DEFICIENCY; PROTEIN DEFICIENCY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKELETAL MUSCLE;

EID: 84908691562     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.09.016     Document Type: Article

References (37)

1. Orr A.W., Hastings N.E., Blackman B.R., et al. Complex regulation and function of the inflammatory smooth muscle cell phenotype in atherosclerosis. J.Vasc. Res. 2010, 47:168-180.
2. Bot P.T., Hoefer I.E., Piek J.J., et al. Hyaluronic acid: targeting immune modulatory components of the extracellular matrix in atherosclerosis. Curr. Med. Chem. 2008, 15:786-791.
3. Merline R., Schaefer R.M., Schaefer L. The matricellular functions of small leucine-rich proteoglycans (SLRPs). J.Cell Commun. Signal. 2009, 3:323-335.
4. Kalamajski S., Oldberg A. The role of small leucine-rich proteoglycans in collagen fibrillogenesis. Matrix Biol. J. Int. Soc. Matrix Biol. 2010, 29:248-253.
5. Hildebrand A., Romaris M., Rasmussen L.M., et al. Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor beta. Biochem. J. 1994, 302(Pt 2):527-534.
6. Shanahan C.M., Cary N.R., Osbourn J.K., et al. Identification of osteoglycin as a component of the vascular matrix. Differential expression by vascular smooth muscle cells during neointima formation and in atherosclerotic plaques. Arterioscler. Thromb. Vasc. Biol. 1997, 17:2437-2447.
7. Fernandez B., Kampmann A., Pipp F., et al. Osteoglycin expression and localization in rabbit tissues and atherosclerotic plaques. Mol. Cell. Biochem. 2003, 246:3-11.
8. Strom A., Ahlqvist E., Franzen A., et al. Extracellular matrix components in atherosclerotic arteries of Apo E/LDL receptor deficient mice: an immunohistochemical study. Histol. Histopathol. 2004, 19:337-347.
9. Heegaard A.M., Corsi A., Danielsen C.C., et al. Biglycan deficiency causes spontaneous aortic dissection and rupture in mice. Circulation 2007, 115:2731-2738.
10. Shimizu-Hirota R., Sasamura H., Kuroda M., et al. Extracellular matrix glycoprotein biglycan enhances vascular smooth muscle cell proliferation and migration. Circ. Res. 2004, 94:1067-1074.
11. Al Haj Zen A., Caligiuri G., Sainz J., et al. Decorin overexpression reduces atherosclerosis development in apolipoprotein E-deficient mice. Atherosclerosis 2006, 187:31-39.
12. Tasheva E.S., Koester A., Paulsen A.Q., et al. Mimecan/osteoglycin-deficient mice have collagen fibril abnormalities. Mol. Vis. 2002, 8:407-415.
13. Beecher N., Carlson C., Allen B.R., et al. An x-ray diffraction study of corneal structure in mimecan-deficient mice. Investig. Ophthalmol. Vis. Sci. 2005, 46:4046-4049.
14. Williamson R.E., Darrow K.N., Giersch A.B., et al. Expression studies of osteoglycin/mimecan (OGN) in the cochlea and auditory phenotype of Ogn-deficient mice. Hear. Res. 2008, 237:57-65.
15. Reddick R.L., Zhang S.H., Maeda N. Atherosclerosis in mice lacking apo E. Evaluation of lesional development and progression. Arterioscler. Thromb. J. Vasc. Biol./Am. Heart Assoc. 1994, 14:141-147.
16. Scott J.E., Dorling J. Differential staining of acid glycosaminoglycans (mucopolysaccharides) by alcian blue in salt solutions. Histochimie 1965, 5:221-233.
17. Junqueira L.C.V., Bignolas G., Brentani R.R. Picrosirius staining plus polarization microscopy, a specific method for collagen detection in tissue sections. Histochem. J. 1979, 11:435-447.
18. Paigen B., Morrow A., Holmes P.A., et al. Quantitative assessment of atherosclerotic lesions in mice. Atherosclerosis 1987, 68:231-240.
19. Shami A., Gustafsson R., Kalamajski S., et al. Fibromodulin deficiency reduces low-density lipoprotein accumulation in atherosclerosis plaque in apolipoprotein E-null mice. Arterioscler. Thromb. Vasc. Biol. 2012, 33:354-361.
20. Jian J., Zheng Z., Zhang K., et al. Fibromodulin promoted invitro and invivo angiogenesis. Biochem. Biophys. Res. Commun. 2013, 436:530-535.
21. Kampmann A., Fernandez B., Deindl E., et al. The proteoglycan osteoglycin/mimecan is correlated with arteriogenesis. Mol. Cell. Biochem. 2009, 322:15-23.
22. Scott R.A., Paderi J.E., Sturek M., et al. Decorin mimic inhibits vascular smooth muscle proliferation and migration. PloS One 2013, 8:e82456.
23. Marzoll A., Melchior-Becker A., Cipollone F., et al. Small leucine-rich proteoglycans in atherosclerotic lesions: novel targets of chronic statin treatment?. J.Cell. Mol. Med. 2011, 15:232-243.
24. Fischer J.W., Kinsella M.G., Clowes M.M., et al. Local expression of bovine decorin by cell-mediated gene transfer reduces neointimal formation after balloon injury in rats. Circ. Res. 2000, 86:676-683.
25. Ge G., Seo N.S., Liang X., et al. Bone morphogenetic protein-1/tolloid-related metalloproteinases process osteoglycin and enhance its ability to regulate collagen fibrillogenesis. J.Biol. Chem. 2004, 279:41626-41633.
26. Gu X.S., Lei J.P., Shi J.B., et al. Mimecan is involved in aortic hypertrophy induced by sinoaortic denervation in rats. Mol. Cell. Biochem. 2011, 352:309-316.
27. Bentz H., Nathan R.M., Rosen D.M., et al. Purification and characterization of a unique osteoinductive factor from bovine bone. J.Biol. Chem. 1989, 264:20805-20810.
28. Hamajima S., Hiratsuka K., Kiyama-Kishikawa M., et al. Effect of low-level laser irradiation on osteoglycin gene expression in osteoblasts. Lasers Med. Sci. 2003, 18:78-82.
29. Funderburgh J.L., Corpuz L.M., Roth M.R., et al. Mimecan, the 25-kDa corneal keratan sulfate proteoglycan, is a product of the gene producing osteoglycin. J.Biol. Chem. 1997, 272:28089-28095.
30. Svensson L., Aszodi A., Reinholt F.P., et al. Fibromodulin-null mice have abnormal collagen fibrils, tissue organization, and altered lumican deposition in tendon. J.Biol. Chem. 1999, 274:9636-9647.
31. Zhang G., Chen S., Goldoni S., et al. Genetic evidence for the coordinated regulation of collagen fibrillogenesis in the cornea by decorin and biglycan. J.Biol. Chem. 2009, 284:8888-8897.
32. Johnson R.C., Leopold J.A., Loscalzo J. Vascular calcification: pathobiological mechanisms and clinical implications. Circ. Res. 2006, 99:1044-1059.
33. Tasheva E.S., Klocke B., Conrad G.W. Analysis of transcriptional regulation of the small leucine rich proteoglycans. Mol. Vis. 2004, 10:758-772.
34. Tanaka K., Matsumoto E., Higashimaki Y., et al. Role of osteoglycin in the linkage between muscle and bone. J.Biol. Chem. 2012, 287:11616-11628.
35. Fischer J.W., Steitz S.A., Johnson P.Y., et al. Decorin promotes aortic smooth muscle cell calcification and colocalizes to calcified regions in human atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol. 2004, 24:2391-2396.
36. -/- mice. Arterioscler. Thromb. Vasc. Biol. 2006, 26:2117-2124.
37. Petretto E., Sarwar R., Grieve I., et al. Integrated genomic approaches implicate osteoglycin (Ogn) in the regulation of left ventricular mass. Nat. Genet. 2008, 40:546-552.